Monopar Therapeutics Inc. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Monopar Therapeutics Inc. (MNPR) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$7.21 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-12
- Monopar Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$7.21K, a 107.25% decline year-over-year.
- Monopar Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$32.87K.
- Monopar Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was -$65.88K.
- Monopar Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-06-30 was $99.36K, a 2367.37% increase year-over-year.
- Monopar Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $95.40K, a 90.32% increase from fiscal 2024.
- Monopar Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was $50.12K.
- Monopar Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was -$23.07K, a 290.66% decline from fiscal 2022.
- Monopar Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was $12.10K.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month as first filed | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$7.21K 10-Q · filed 2026-08-12 | -$40.07K derived: sum of 2 quarters · filed 2026-08-12 | |||
| 2026-03-31 | -$32.87K 10-Q · filed 2026-08-12 | ||||
| 2025-12-31 | $95.40K 10-K · filed 2026-03-27 | ||||
| 2025-09-30 | -$65.88K 10-Q · filed 2025-11-13 | $33.48K derived: sum of 2 quarters · filed 2026-08-12 | -$24.29K derived: sum of 3 quarters · filed 2026-08-12 | ||
| 2025-06-30 | $99.36K 10-Q · filed 2026-08-12 | $41.59K derived: sum of 2 quarters · filed 2026-08-12 | |||
| 2025-03-31 | -$57.78K 10-Q · filed 2026-08-12 | ||||
| 2024-12-31 | $50.12K 10-K · filed 2026-03-27 | ||||
| 2024-09-30 | -$19.25K 10-Q · filed 2025-11-13 | -$15.22K derived: sum of 2 quarters · filed 2025-11-13 | $3.14K derived: sum of 3 quarters · filed 2025-11-13 | ||
| 2024-06-30 | $4.03K 10-Q · filed 2025-11-13 | $22.39K derived: sum of 2 quarters · filed 2025-11-13 | |||
| 2024-03-31 | $18.36K 10-Q · filed 2025-11-13 | ||||
| 2023-12-31 | -$23.07K 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | -$3.27K 10-Q · filed 2024-11-08 | -$27.84K derived: sum of 2 quarters · filed 2024-11-08 | -$4.99K derived: sum of 3 quarters · filed 2024-11-08 | ||
| 2023-06-30 | -$24.57K 10-Q · filed 2024-11-08 | -$1.72K derived: sum of 2 quarters · filed 2024-11-08 | |||
| 2023-03-31 | $22.84K 10-Q · filed 2024-11-08 | ||||
| 2022-12-31 | $12.10K 10-K · filed 2024-03-28 | ||||
| 2022-09-30 | $25.52K 10-Q · filed 2023-11-09 | $46.73K derived: sum of 2 quarters · filed 2023-11-09 | $46.15K derived: sum of 3 quarters · filed 2023-11-09 | ||
| 2022-06-30 | $21.21K 10-Q · filed 2023-11-09 | $20.63K derived: sum of 2 quarters · filed 2023-11-09 | |||
| 2022-03-31 | -$584.00 10-Q · filed 2023-11-09 | -$2.46M 10-Q · filed 2022-05-12 | |||
| 2021-03-31 | -$1.88M 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |